Business Context and Reporting Period
Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company based in Israel, focused on developing therapeutics for fibrotic and inflammatory diseases. This Form 8-K, dated February 21, 2023, discloses the Company's consolidated audited financial statements and Management's Discussion and Analysis for the fiscal year ended December 31, 2022. The Company is an emerging growth company with no product revenue to date.
Key Financial Metrics
| Metric (in thousands) | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and Development Expenses | $16,977 | $6,334 |
| General and Administrative Expenses | $11,556 | $6,033 |
| Total Operating Expenses | $28,533 | $12,367 |
| Net Loss | $(27,646) | $(12,478) |
| Net Cash Used in Operating Activities | $(20,370) | $(12,374) |
| Net Cash Provided by Investing Activities | $19,533 | $(45,186) |
| Net Cash Used in Financing Activities | $(808) | $61,074 |
| Accumulated Deficit (as of Dec 31, 2022) | ~$(64,000) | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by approximately $16.2 million (131%) from 2021 to 2022. R&D expenses rose 168% to $17.0 million, driven by increased headcount and payments for clinical/pre-clinical activities. G&A expenses rose 92% to $11.6 million due to higher headcount, professional fees, insurance, and share-based compensation.
- Net Loss: The net loss more than doubled to $27.6 million in 2022 compared to $12.5 million in 2021.
- Cash Flow: Net cash used in operating activities increased by 65% to $20.4 million. Conversely, investing activities shifted from a net use of $45.2 million in 2021 to a net provision of $19.5 million in 2022, primarily due to investments in short-term deposits. Financing activities shifted from a net provision of $61.1 million in 2021 (driven by private placements) to a net use of $0.8 million in 2022.
Guidance, Outlook, and Risks
- Liquidity: Management estimates existing cash, cash equivalents, and bank deposits will fund operations through March 31, 2024. The Company anticipates incurring net losses for the foreseeable future and will require substantial additional financing to advance clinical trials and commercialization.
- Clinical Progress: The Company is actively recruiting for a Phase 2 study of its lead candidate, CM-101, in Primary Sclerosing Cholangitis (PSC), expanding to include a high-dose arm. A Phase 2 trial in Systemic Sclerosis (SSc) is planned for the first half of 2023. A recent Phase 2 study in NASH met its primary safety endpoint and showed encouraging activity in secondary endpoints.
- Financing Activities: During 2022, the Company sold 130,505 ADSs via its ATM facility for gross proceeds of $275,000. The Company maintains an ATM facility with Cantor Fitzgerald for up to $75 million.
- Risks: Key risks include the inability to raise additional capital on favorable terms, which could force delays or termination of development programs. The Company is also exposed to foreign currency exchange risk (USD vs. New Israeli Shekel), though management does not expect a 10% fluctuation to be material.
Investor Verification Checklist
- Verify the accuracy of the cash runway estimate (through March 31, 2024) against current cash burn rates.
- Confirm the status of the Phase 2 PSC trial expansion and the timeline for the SSc trial initiation.
- Review the terms of the ATM facility and the Company's ability to access capital markets given the accumulated deficit of ~$64 million.
- Monitor the receipt of the remaining $183,000 tax benefit expected in 2023.
- Assess the impact of foreign currency fluctuations on future operating expenses incurred in Israel.